| 05/04 | Idogen publishes interim report for 1 January - 31 March 2022 | AQ |
| 05/04 | Idogen AB Reports Earnings Results for the First Quarter Ended March 31, 2022 | CI |
| 04/19 | Idogen Receives Approval From Swedish, Norwegian Authorities For Clinical Trial Of Hemo.. | MT |
| 04/19 | BIOSTOCK : Idogen's study approved in Norway and Sweden | AQ |
| 04/19 | Idogen AB Announces Study Approval in Norway and Sweden | CI |
| 04/13 | Idogen Appoints Chief Medical, Chief Regulatory Officers | MT |
| 04/13 | Idogen strengthens the organization before the clinical development phase | AQ |
| 04/13 | Idogen Strengthens the Organization Before the Clinical Development Phase | CI |
| 04/13 | Idogen AB Announces Executive Appointments | CI |
| 04/11 | Idogen receives approval from the Norwegian Medicines Agency, NoMA, for the start of it.. | AQ |
| 04/11 | Idogen AB Receives Approval from the Norwegian Medicines Agency, Noma, for the Start of.. | CI |
| 03/31 | Idogen publishes annual report for 2021 | AQ |
| 03/30 | Idogen Appoints Two Contract Research Groups To Run Early-stage Trial Of Hemophilia Tre.. | MT |
| 03/30 | Idogen signs strategic collaboration agreement with contract research companies | AQ |
| 03/30 | Idogen AB Signs Strategic Collaboration Agreement with KLIFO A/S and 4Pharma | CI |
| 03/28 | BIOSTOCK : Principal investigator on Idogen's clinical study with IDO 8 | AQ |
| 03/28 | Idogen Receives Approval from the Swedish Medical Products Agency for the Clinical Phas.. | CI |
| 03/22 | Idogen updates in connection with the Swedish Medical Products Agency's approval of pha.. | AQ |
| 03/22 | Idogen AB Updates in Connection with the Swedish Medical Products Agency's Approval of .. | CI |
| 03/14 | BIOSTOCK : Leading transplant surgeon about Idogen's cell therapy | AQ |
| 02/14 | Idogen announces outcome of rights issue | AQ |
| 01/27 | Idogen presents the company's technology platform at a scientific congress | AQ |
| 01/20 | Idogen publishes prospectus due to upcoming rights issue | AQ |
| 01/20 | Bulletin from the extraordinary general meeting in Idogen AB | AQ |
| 01/19 | Idogen publishes interim report for 1 January - 31 December 2021 | AQ |
| 01/19 | Idogen AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 | CI |
| 01/19 | Idogen AB Reports Earnings Results for the Full Year Ended December 31, 2021 | CI |
| 01/11 | Idogen adds Norway for its clinical phase 1/2a study and submits an application for app.. | AQ |
| 01/11 | Idogen AB Submits Application to Norwegian Medicines Agency to Begin Clinical Phase 1/2.. | CI |
| 2021 | BIOSTOCK : Idogen submits clinical trial application | AQ |
| 2021 | Idogen Submits Clinical Trial Application | CI |
| 2021 | Idogen submits an application to the Swedish Medical Products Agency to initiate a clin.. | AQ |
| 2021 | Idogen AB Submits an Application to the Swedish Medical Products Agency to Initiate A C.. | CI |
| 2021 | Idogen carries out a fully guaranteed rights issue of units of approximately SEK 50.4 m.. | AQ |
| 2021 | BIOSTOCK : Idogen has reached milestone in clinical trial preparations | AQ |
| 2021 | Idogen Completes Optimization of Cell Therapy Manufacturing Process | MT |
| 2021 | CORRECTION OF DATE IN PRESS RELEASE : "Idogen has successfully completed the optimization .. | AQ |
| 2021 | Idogen has successfully completed the optimization of the GMP manufacturing process for.. | AQ |
| 2021 | Idogen AB Completes the Optimization of the GMP Manufacturing Process for the First Cli.. | CI |
| 2021 | Idogen's Nomination Committee proposes re-election of Board of Directors | AQ |
| 2021 | IDOGEN : Interim report Q3 2021 | PU |
| 2021 | IDOGEN : publishes interim report for 1 January - 30 September 2021 | AQ |
| 2021 | Idogen AB Reports Earnings Results for the Third Quarter and Nine Months Ended Septembe.. | CI |
| 2021 | IDOGEN : announces outcome of exercise period for Series TO 4 subscription warrants | AQ |
| 2021 | IDOGEN : The last day for trading in the warrants of series TO 4 in Idogen AB is today, Oc.. | AQ |
| 2021 | IDOGEN : Board of Directors and management of Idogen AB to exercise all of their TO 4 warr.. | AQ |
| 2021 | IDOGEN : Exercise period for Series TO 4 subscription warrants in Idogen begins today | AQ |
| 2021 | IDOGEN : continues to optimize its production method prior to the start of the patient stu.. | AQ |
| 2021 | Idogen Continues to Optimize Its Production Method Prior to the Start of the Patient St.. | CI |
| 2021 | IDOGEN : Interim report Q2 2021 | PU |
| 2021 | IDOGEN : publishes interim report for 1 January - 30 June 2021 | AQ |
| 2021 | Idogen AB Publ Reports Earnings Results for the Second Quarter Ended June 30, 2021 | CI |
| 2021 | IDOGEN : European patent granted relevant to Idogen's cell therapy for hemophilia A | AQ |
| 2021 | BIOSTOCK : Idogen's CEO on World Transplant Day and IDO T against organ rejection | AQ |
| 2021 | IDOGEN : Bulletin from the annual general meeting in Idogen AB on May 11, 2021 | AQ |
| 2021 | Idogen AB Appoints Lennart Svensson as New Board Member | CI |
| 2021 | IDOGEN : publishes interim report for 1 January - 31 March 2021 | AQ |
| 2021 | Idogen AB Publ Reports Earnings Results for the First Quarter Ended March 31, 2021 | CI |
| 2021 | IDOGEN : BioStock interview with Åsa Schiött, Chief Scientific Officer at Idogen | AQ |
| 2021 | IDOGEN : BioStock interview with Rolf Ljung, scientific advisor to Idogen | AQ |
| 2021 | IDOGEN : The European Patent Office intends to grant Idogen's patent application relevant .. | PU |
| 2021 | IDOGEN : The European Patent Office intends to grant Idogen's patent application relevant .. | AQ |
| 2021 | Idogen AB Receives Confirmation the European Patent Office Intends to Grant A Patent Ap.. | CI |
| 2021 | IDOGEN : publishes Year-end report for 2020 | AQ |
| 2021 | Idogen AB Announces Executive Changes | CI |
| 2021 | Idogen AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2020 | CI |
| 2020 | IDOGEN : Interim report January 1– September 30, 2020 | PU |
| 2020 | IDOGEN AB : Interim report January 1- September 30, 2020 | AQ |
| 2020 | Idogen AB Reports Earnings Results for the Third Quarter Ended September 30, 2020 | CI |
| 2020 | IDOGEN : provides update on timelines for the development of the tolerogenic cell therapy .. | PU |
| 2020 | IDOGEN : provides update on timelines for the development of the tolerogenic cell therapy .. | AQ |
| 2020 | Idogen Provides Update on Timelines for the Development of the Tolerogenic Cell Therapy.. | CI |
| 2020 | IDOGEN AB : Interim report | AQ |
| 2020 | IDOGEN PUBL : has been approved for listing on Nasdaq First North Growth Market | PU |
| 2020 | IDOGEN PUBL : cell therapy product successfully produced by GMP-certified manufacturing pa.. | AQ |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
